Recommendation
Routine use of fibrates for primary prevention of cardiovascular disease is not recommended
Essencial: Afegint valor a la pràctica clínica [Essencial: Adding value to the clinical practice] (Essencial Salut)
Although fibrates (such as fenofibrate, bezafibrate, and gemfibrozil) lower triglyceride levels and increase HDL cholesterol, clinical trials have not shown a meaningful reduction in major cardiovascular events (such as myocardial infarction or stroke) in individuals without previous cardiovascular disease. The evidence points to only modest effects, with no significant impact on mortality or overall survival, and potential adverse effects including myopathy, elevated liver enzymes, or gallstones. Major clinical practice guidelines do not recommend the routine use of fibrates for primary prevention. Statins remain the treatment of choice for people at elevated cardiovascular risk. Therefore, routine use of fibrates in this context is not recommended, except in specific cases such as severe hypertriglyceridemia or statin intolerance.
Language:
Spanish
Specialty:
Cardiology, Family Medicine, Internal medicine
Publication Year:
2025
Intervention type:
Drugs (non-chemotherapy drugs)
Recommendation type:
Low value